National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

Lutetium (177Lu) Oxodotreotide (Lutathera®) for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor (SSTR) positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.

 

NCPE Assessment Process Complete
Rapid review commissioned 23/10/2018
Rapid review completed 16/11/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended